158 related articles for article (PubMed ID: 36644546)
1. Enhanced control of bioactivity of tissue plasminogen activator (tPA) through domain-directed enzymatic oxidation of terminal galactose.
Mahdi WA; Absar MS; Choi S; Yang VC; Kwon YM
Bioimpacts; 2022; 12(6):479-486. PubMed ID: 36644546
[No Abstract] [Full Text] [Related]
2. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs.
Liang JF; Park YJ; Song H; Li YT; Yang VC
J Control Release; 2001 May; 72(1-3):145-56. PubMed ID: 11389993
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis.
Absar S; Choi S; Ahsan F; Cobos E; Yang VC; Kwon YM
Thromb Res; 2013 Mar; 131(3):e91-9. PubMed ID: 23269380
[TBL] [Abstract][Full Text] [Related]
4. Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis.
Absar S; Choi S; Yang VC; Kwon YM
J Control Release; 2012 Jan; 157(1):46-54. PubMed ID: 21930168
[TBL] [Abstract][Full Text] [Related]
5. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs.
Liang JF; Li YT; Song H; Park YJ; Naik SS; Yang VC
J Control Release; 2002 Jan; 78(1-3):67-79. PubMed ID: 11772450
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.
Liang JF; Li YT; Connell ME; Yang VC
AAPS PharmSci; 2000; 2(1):E7. PubMed ID: 11741223
[TBL] [Abstract][Full Text] [Related]
7. Serum albumin-protamine conjugate for biocompatible platform for targeted delivery of therapeutic macromolecules.
Absar S; Nahar K; Choi S; Ahsan F; Yang VC; Kwon YM
J Biomed Mater Res A; 2014 Aug; 102(8):2481-90. PubMed ID: 23946132
[TBL] [Abstract][Full Text] [Related]
8. A novel heparin/protamine-based pro-drug type delivery system for protease drugs.
Liang JF; Song H; Li YT; Yang VC
J Pharm Sci; 2000 May; 89(5):664-73. PubMed ID: 10756332
[TBL] [Abstract][Full Text] [Related]
9. A prodrug approach for delivery of t-PA: construction of the cationic t-PA prodrug by a recombinant method and preliminary in vitro evaluation of the construct.
Song H; Liang JF; Yang VC
ASAIO J; 2000; 46(6):663-8. PubMed ID: 11110262
[TBL] [Abstract][Full Text] [Related]
10. Functional properties of carbohydrate-depleted tissue plasminogen activator.
Little SP; Bang NU; Harms CS; Marks CA; Mattler LE
Biochemistry; 1984 Dec; 23(25):6191-5. PubMed ID: 6441597
[TBL] [Abstract][Full Text] [Related]
11. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
Yang VC; Naik SS; Song H; Dombkowski AA; Crippen G; Liang JF
J Control Release; 2005 Dec; 110(1):164-76. PubMed ID: 16260060
[TBL] [Abstract][Full Text] [Related]
12. Application of "ATTEMPTS" for drug delivery.
Naik SS; Liang JF; Park YJ; Lee WK; Yang VC
J Control Release; 2005 Jan; 101(1-3):35-45. PubMed ID: 15588892
[TBL] [Abstract][Full Text] [Related]
13. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro.
Runge MS; Bode C; Matsueda GR; Haber E
Biochemistry; 1988 Feb; 27(4):1153-7. PubMed ID: 3130094
[TBL] [Abstract][Full Text] [Related]
14. The effect of polymerised fibrin on the catalytic activities of one-chain tissue-type plasminogen activator as revealed by an analogue resistant to plasmin cleavage.
Petersen LC; Johannessen M; Foster D; Kumar A; Mulvihill E
Biochim Biophys Acta; 1988 Feb; 952(3):245-54. PubMed ID: 2962643
[TBL] [Abstract][Full Text] [Related]
15. Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis.
Absar S; Kwon YM; Ahsan F
J Control Release; 2014 Mar; 177():42-50. PubMed ID: 24417965
[TBL] [Abstract][Full Text] [Related]
16. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation.
Stricker RB; Wong D; Shiu DT; Reyes PT; Shuman MA
Blood; 1986 Jul; 68(1):275-80. PubMed ID: 2941084
[TBL] [Abstract][Full Text] [Related]
17. beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation.
Bu C; Gao L; Xie W; Zhang J; He Y; Cai G; McCrae KR
Arthritis Rheum; 2009 Feb; 60(2):559-68. PubMed ID: 19180513
[TBL] [Abstract][Full Text] [Related]
18. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen.
Andrade-Gordon P; Strickland S
Biochemistry; 1986 Jul; 25(14):4033-40. PubMed ID: 2943315
[TBL] [Abstract][Full Text] [Related]
19. Hybrid molecules: insights into plasminogen activator function.
Runge MS; Bode C; Haber E; Quertermous T
Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
[TBL] [Abstract][Full Text] [Related]
20. Dual effect of synthetic plasmin substrates on plasminogen activation.
Kolev K; Owen WG; Machovich R
Biochim Biophys Acta; 1995 Mar; 1247(2):239-45. PubMed ID: 7696314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
